AGC Biologics has successfully manufactured more than 200 biological projects for pre-clinical studies through commercial approvals. Our global facilities span three continents and offer multiple cGMP manufacturing lines at a variety of scales for mammalian cell culture and microbial fermentation.
We develop and manufacture diverse cell therapies including CD34+ hematopoietic stem cells, autologous and allogenic T-cells, and NK cells. Our cell therapy capabilities cover numerous technologies, ranging from closed to open systems at different scales, depending on client needs. We also develop and manufacture adeno-associated viral vectors, lenti viral vectors and retro viral vectors. Our ready-to-use platform capabilities are built on cell factories (up to 48L) and bioreactors (up to 200L) using adherent processes, designed entirely in-house.
BIO Asia–Taiwan 2022 Onsite + Online will showcase Taiwan's growing digital advantage in the biomed sector and spotlight biotech, pharmaceutical, medical devices, precision medicine advances, as well as AI applications, ICT and IoT technologies, and new healthcare/medical investment opportunities.